Related Experiment Video
Updated: Apr 1, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
22.2K
T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition
Roch Houot1, Liora Michal Schultz2, Aurélien Marabelle3
1CHU Rennes, Service Hématologie Clinique, Rennes, France. INSERM U917, Rennes, France.
Cancer Immunology Research
|October 7, 2015
Summary
T-cell-based cancer immunotherapies, including adoptive cell transfer and immune checkpoint inhibitors, show significant promise. This review explores current clinical trials and future applications of these T-cell therapies for cancer treatment.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Tumor immunotherapy has demonstrated significant efficacy in cancer patients.
- T-cell-based therapies represent a highly promising area within cancer immunotherapy.
Purpose of the Study:
- To review various T-cell-based immunotherapy strategies currently under clinical investigation.
- To provide perspective on the present and future applications of these T-cell therapies.
Main Methods:
- Review of current clinical trials involving T-cell-based cancer immunotherapies.
- Analysis of different T-cell-based therapeutic approaches.
Main Results:
- Identified adoptive cell transfer, genetically engineered T cells, and immune checkpoint inhibitors as key T-cell-based strategies.
- Highlighted the demonstrable efficacy of these therapies in patients with cancer.
Conclusions:
- T-cell-based immunotherapies are a rapidly advancing field with substantial clinical impact.
- Ongoing research and clinical trials are crucial for realizing the full potential of these treatments.
Related Concept Videos
01:27Tumor Immunotherapy
2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
01:40Cell-mediated Immune Responses
86.4K
Overview
86.4K
01:22T Cell Activation and Clonal Selection
17.4K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
17.4K
01:27Cytotoxic T Cells-mediated Immune Response
8.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.3K